Archive for July, 2010

Understanding Stock Charts – The Basics

Friday, July 2nd, 2010

When used with other stock indicators the following  charting skills can help you greatly improve your trades.

Resistance levels are price levels that a stock has a difficult time busting through. The bottom resistance is called a floor.  The upper resistance is called a ceiling. Typically, buyers enter the market around the floor price to stabilize the price and possibly drive the share price back up. When a stock is reaching its ceiling, sellers will enter the market stopping the upward momentum and even driving the stock price back down. The best way to spot resistance levels on a stock chart is to find prices where the stock moves horizontally. For example, if a stock is trading around 15 and then trades down to 10 but then begins to move sideways at 10 and eventually heads back up in price, then 10 is probably a price floor. The more times a resistance level is tested, the stronger it becomes . However, if a resistance level is broken it usually results in upward momentum. For example, if the stock mentioned above broke through its price floor of 10 then the price floor would become the price ceiling. Keep in mind that resistance levels are usually price ranges not a specific stock price.

Another important feature of stock charts is volume (the number of shares traded each day). Most stock charts will show the volume of shares traded along the bottom of the chart. Look for higher than normal trading activity. If a stock is trading higher on high volume it is much more likely to continue. However, if a stock is trading higher on low volume, it may be a sign of uncertainty and the gains may be short lived. Without the conformation of volume it is very difficult to be sure of any price move or new trend.

A gap is when a stock “jumps” up or down leaving a blank area on a chart. For example, if a stock closed the previous day at $12 but opened the next day at $14, this would be a gap up. In this example the gap will become a resistance floor. However, if the gap is penetrated, it will often fill the entire gap or close the blank space before resuming its trend. Once the gap has been closed it loses much of its significance on stock charts.

Here’s a quick clip for all you beginners with some very basic, but important information about reading stock charts:

Using stock charts can be a helpful tool. However, stock charts use historical data and future price movements may differ. Most active traders rely heavily on stock charts and indicators to make their investment decisions.

Buzz Stocks Week in Review – IDT, CWLZ, PEIX, ARNA

Friday, July 2nd, 2010

Average Weekly Gain: 37.3%


Monday: Our Buzz Stock of the Day on June 28, IDT Corp. (NYSE: IDT) had a great week. IDT, which blends a strange pairing of telecom and energy had positive momentumthroughout the week. Shares began their climb on Monday, after a CNBC interview in which CEO Howard Jonas outlined the company’s shale properties and oil extraction technology. IDT’s energy business, Genie Energy, holds IDT’s interests in the American Shale Oil, LLC (AMSO), a joint oil shale research and development venture in Colorado with Total, S.A.; and in Israel Energy Initiatives (IEI), which holds an exclusive shale oil exploration and production license in the Shfela region of Israel. According to Jonas, it costs IDT Corp. $25 per-barrel to extract oil from shale rock. This figure is about $10 less than ultra-deep water fuel extraction — the kind of extraction that was being used by British Petroleum (NYSE: BP) in the Gulf of Mexico.

Up as much as 57 percent since our post.

Tuesday: On Tuesday, we featured Cowlitz Bancorp. (Pink Sheets: CWLZ) as our Buzz Stock of the Day. Cowlitz shares were up about 25 percent from Monday’s close, in morning trading on Tuesday after the company announced that it presented an updated plan to regain compliance with two Nasdaq Listing Rules with which it is not in compliance and requested a 90-day exception to the continued listing standards. Unfortunately, Cowlitz was de-listed from the Nasdaq on Thursday, July 1. Cowlitz received a  delisting determination letter from Nasdaq due to the Company not being in compliance with the minimum 500,000 publicly held shares requirement set forth in Listing Rule 5550(a)(4), on May 12.

Wednesday: Shares of Pacific Ethanol, Inc. (Nasdaq: PEIX) surged almost 60 percent on Wednesday, after the company announced that four of its subsidiaries had emerged out of bankruptcy. The plant subsidiaries, which are now owned by a newly formed holding company, will continue to be staffed, managed and operated by Pacific Ethanol under a fee and profit-sharing arrangement negotiated with the owners of the newly formed holding company. Pacific Ethanol, Inc. eliminated approximately $290 million in debt and other liabilities from its balance sheet. The bankruptcy did not affect the Company’s ownership structure and the Company continues to be owned by its existing common and preferred stockholders.
Up as much as 31 percent since our post.

Thursday: Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) was up 20 percent from Wednesday’s close, in morning trading on Thursday after the company announced that Japanese drug maker, Eisai, Inc. will market Arena’s obesity treatment lorcaserin in the U.S. The U.S. Food and Drug Administration is already reviewing lorcaserin, and a decision is expected on Oct. 22. The main concern with lorcaserin is that patients treated with the drug in two pivotal phase III studies didn’t lose much weight — a little more than 3% on a placebo adjusted basis. The biggest plus in lorcaserin’s corner is the drug’s safety and tolerability, which appear better than competing drugs.
Up as much as 24 percent since our post.

Don’t forget to sign up for our FREE Buzz Stocks alerts!

Arena Pharmaceuticals, Inc. (ARNA) – Buzz Stock of the Day

Thursday, July 1st, 2010

Shares of drug maker Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) surged 20 percent from Wednesday’s close, in morning trading on Thursday after it was announced that Japanese drug maker, Eisai, Inc. will market Arena’s obesity treatment lorcaserin in the U.S.

“Execution of this commercial agreement is a major milestone in our plans for lorcaserin,” said Jack Lief, Arena’s President and Chief Executive Officer. “We believe in Eisai’s human health care mission to satisfy unmet medical needs and increase benefits to patients and their families.”

Here are a few highlights from the deal:

  • $50 million initial upfront (kind of small when considering the potential of the drug)
  • $90 million upon FDA Approval (PDUFA October 22nd) bringing upfront for US marketing rights to $140 million
  • $1.16B in one-time purchase price adjustments after certain sales goals.
  • 31.5-36.5% of annual Lorcaserin sales
  • [–quote–]
    The U.S. Food and Drug Administration is already reviewing lorcaserin, and an decision is expected on Oct. 22. The main concern with lorcaserin is that patients treated with the drug in two pivotal phase III studies didn’t lose much weight — a little more than 3% on a placebo adjusted basis. The biggest plus in lorcaserin’s corner is the drug’s safety and tolerability, which appear better than competing drugs.

    “With Eisai, we have the right company to market lorcaserin in the United States, the right type of agreement to optimize lorcaserin’s medical and commercial potential and the shared recognition that it is the right time to enter into this agreement to prepare for launch following FDA approval,” Lief said.